Aurolife Pharma, LLC Recalls

All product recalls associated with Aurolife Pharma, LLC.

Get alerts for this brand

Recall Summary

Total Recalls

14

Past Year

0

Class I (Serious)

0

Most Recent

May 2023

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 1–14 of 14 recalls

Glycopyrrolate Tablets (Aurolife) – Impurity Specification Failure (2023)

Failed Impurities/Degradation Specifications

Class IIILow

FDAMay 18, 2023Nationwide• Aurolife Pharma, LLC

Glycopyrrolate Tablets (Aurolife) – Impurity Specifications (2022)

Failed Impurities/Degradation Specifications

Class IIModerate

FDADec 16, 2022Nationwide• Aurolife Pharma, LLC

Glycopyrrolate Tablets (Aurolife) – Glass Contamination (2022)

Presence of Foreign Substance: Complaint for pieces of glass discovered in a sealed bottle which came from equipment within the packaging room.

Class II

Moderate

FDAMar 17, 2022Nationwide• Aurolife Pharma, LLC

Fexofenadine Tablets (Aurolife) – Impurity Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Fexofenadine HCL Tablets (Aurolife) – Impurity Specification Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Allergy Relief Tablets (Aurolife) – Impurity Specification Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Allergy Relief Tablets (Aurolife) – Impurity Specification Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Allergy Tablets (Aurolife) – Impurity Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Fexofenadine Hydrochloride Tablets (Aurolife) – Impurity Specification Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Fexofenadine Tablets (Aurolife) – Impurity Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Allergy Tablets (Aurolife) – Impurity Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Allergy Relief Tablets (Aurolife) – Impurity Specification Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Fexofenadine Hydrochloride Tablets (Aurolife) – Impurity Specification Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Wal-Fex Tablets (Aurolife) – Impurity Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 23, 2019Nationwide• Aurolife Pharma, LLC

Stay Informed

Aurolife Pharma, LLC Recalls

Recall Summary

Glycopyrrolate Tablets (Aurolife) – Impurity Specification Failure (2023)

Glycopyrrolate Tablets (Aurolife) – Impurity Specifications (2022)

Glycopyrrolate Tablets (Aurolife) – Glass Contamination (2022)

Fexofenadine Tablets (Aurolife) – Impurity Failure (2019)

Fexofenadine HCL Tablets (Aurolife) – Impurity Specification Failure (2019)

Allergy Relief Tablets (Aurolife) – Impurity Specification Failure (2019)

Allergy Relief Tablets (Aurolife) – Impurity Specification Failure (2019)

Allergy Tablets (Aurolife) – Impurity Failure (2019)

Fexofenadine Hydrochloride Tablets (Aurolife) – Impurity Specification Failure (2019)

Fexofenadine Tablets (Aurolife) – Impurity Failure (2019)

Allergy Tablets (Aurolife) – Impurity Failure (2019)

Allergy Relief Tablets (Aurolife) – Impurity Specification Failure (2019)

Fexofenadine Hydrochloride Tablets (Aurolife) – Impurity Specification Failure (2019)

Wal-Fex Tablets (Aurolife) – Impurity Failure (2019)